2:16 PM
Jan 25, 2019
 |  BC Extra  |  Company News

Pfizer launches China's first pay-for-performance model for cancer

Pfizer Inc. (NYSE:PFE) launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China. The program is the nation's first pay-for-performance insurance for oncology and covers 34 Chinese cities, according to state-run newspaper China Daily.


Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >